Objective: Asthma is a chronic disorder of the airways, in which chemokines coordinate airway inflammation and determine its severity. We aimed to study the chemokine interferonγ-inducible protein 10 kDa (IP10/CXCL10), a member of the CXC receptor 3 (CXCR3) ligand family, at the protein level in the serum of children, to evaluate the association between CXCL10 and exacerbations of childhood asthma.
Methods: Patients experiencing an asthma exacerbation (42 patients) and stable patients (43 patients) were investigated for serum CXCL10 levels.
Results: Patients with an asthma exacerbation expressed significantly higher CXCL10 levels in the serum than stable patients ( < 0.001). Additionally, CXCL10 values were elevated in severe asthma compared with moderate and mild disease ( < 0.001). In patients experiencing asthma exacerbations, higher values of CXCL10 were observed in atopic patients compared with non-atopic patients ( = 0.027) and in uncontrolled and partly controlled patients compared with controlled patients ( = 0.046).
Conclusions: CXCL10 is proposed as an inflammatory serum marker for asthma exacerbations and worsening asthma symptoms. The levels of CXCL10 are representative of the clinical severity of asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02770903.2021.1999465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lung proteomic and metabolomic changes induced by carbon black nanoparticles and high humidity in a mouse asthma model.
Environ Pollut
January 2025
School of Medicine, Taizhou University, Taizhou 318000, China.
Allergic asthma is a significant international concern in respiratory health, which can be exacerbated by the increasing levels of non-allergenic pollutants. This rise in airborne pollutants is a primary driver behind the growing prevalence of asthma, posing a health emergency. Additionally, climatic risk factors can contribute to the onset and progression of asthma.
View Article and Find Full Text PDFCosts of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry.
Adv Ther
January 2025
Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Clinical and Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, MI, Italy.
Introduction: The burden of severe asthma on patients, especially on those with concomitant chronic rhinosinusitis with nasal polyps (CRSwNP), is substantial. Treatment intensification with oral corticosteroids is a common strategy for managing severe asthma exacerbations; however, prolonged exposure to systemic corticosteroids is associated with multisystem toxicity. This study aimed to quantify the association between oral corticosteroid use and annual asthma-related costs in patients with severe asthma with or without CRSwNP.
View Article and Find Full Text PDFAssociation between chronic respiratory diseases and frailty in Chinese elderly: a population-based longitudinal study.
BMJ Open Respir Res
January 2025
Peking University, Beijing, China
Background: Chronic respiratory diseases (CRDs) have been shown to be associated with frailty, but these findings have not yet reached a consensus. The aim of this study was to investigate the association between CRDs and frailty in the elderly using a nationally representative data from China.
Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS) were analysed, including 3309 frailty-free participants followed for three waves from 2011.
Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients.
Rev Alerg Mex
December 2024
Master's in economics, HS Pharmacoeconomic Research, Mexico City, Mexico.
Article Synopsis
- The study aimed to analyze the cost-effectiveness of budesonide/formoterol compared to other asthma treatments at Mexico's National Institute for Respiratory Diseases.
- Budesonide/formoterol had a lower average cost per patient ($733.36 USD) compared to fluticasone/vilanterol ($767.24 USD), and it showed a significant reduction in exacerbations with an incremental cost-effectiveness ratio (ICER) of $613.31 USD for better management.
- Overall, budesonide/formoterol was found to be a very cost-effective treatment option, suggesting it could reduce healthcare costs associated with emergency visits and hospitalizations despite fewer exacerbations per patient.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of North Dakota, Grand Forks, ND, USA.
Background: Alzheimer's disease (AD) is an age-related neurodegenerative disorder affecting nearly 50 million individuals worldwide. Besides aging, various comorbidities can increase the risk of AD, such as asthma. However, the molecular mechanism(s) underlying this asthma-associated AD exacerbation is unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!